端粒相关基因胚系突变中的肝病:患病率、临床、影像、病理特征、结局及危险因素
回顾性多中心分析132例端粒相关基因(TRG)突变患者,95例(72%)存在肝病,肝活检见门窦血管病占48%、晚期纤维化/肝硬化占15%。中位随访21个月,5年无肝移植生存率69%。TRG突变患者肝病发生率高于匹配对照组(OR 12.9,95%CI 7.8-21.3,P<0.001)。
要点
- TRG突变患者肝病患病率72%,显著高于匹配对照组的20%(OR 12.9)。
- 肝活检常见门窦血管病(48%)和晚期纤维化/肝硬化(15%)。
- FIB-4评分≥3.25和≥1个肝硬化危险因素与无肝移植生存差相关。
核心结论
- TRG突变显著增加肝病发生风险,症状可能轻微但可伴严重疾病,门窦血管病和肝硬化是最常见病变,机制可能为多因素。
研究设计与样本
- 回顾性多中心分析,纳入132例TRG突变患者,以转氨酶>30 IU/L和/或肝脏影像异常定义肝病。
- 肝病患病率与社区对照人群(n=1190)按年龄分层并按已知肝病危险因素1:3匹配比较。
主要发现
- 132例TRG突变患者中95例(72%)有肝病,伴肺、血液、皮肤、风湿和眼科TRG疾病者分别占82%、77%、55%、39%和30%。
- 52/95例患者行肝活检,门窦血管病占48%,晚期纤维化/肝硬化占15%。
- 随访21个月(12-54)期间,腹水、肝肺综合征、静脉曲张出血和HCC分别发生于14%、13%、13%和2%的病例。
- 5年无肝移植生存率为69%。
- TRG突变患者肝病发生率高于匹配对照组(80/396,20%),OR 12.9(95%CI 7.8-21.3,P<0.001)。
关键数值与推荐
- FIB-4评分≥3.25和≥1个肝硬化危险因素与较差的无肝移植生存相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIM: Germline mutations of telomere-related genes (TRG) induce multiorgan dysfunction, and liver-specific manifestations have not been clearly outlined. We aimed to describe TRG mutations-associated liver diseases. APPROACH AND RESULTS: Retrospective multicenter analysis of liver disease (transaminases > 30 IU/L and/or abnormal liver imaging) in patients with TRG mutations. Main measurements were characteristics, outcomes, and risk factors of liver disease in a TRG mutations cohort. The prevalence of liver disease was compared to a community-based control group (n = 1190) stratified for age and matched 1:3 for known risk factors of liver disease. Among 132 patients with TRG mutations, 95 (72%) had liver disease, with associated lung, blood, skin, rheumatological, and ophthalmological TRG diseases in 82%, 77%, 55%, 39%, and 30% of cases, respectively. Liver biopsy was performed in 52/95 patients, identifying porto-sinusoidal vascular disease in 48% and advanced fibrosis/cirrhosis in 15%. After a follow-up of 21 months (12-54), ascites, hepato-pulmonary syndrome, variceal bleeding, and HCC occurred in 14%, 13%, 13%, and 2% of cases, respectively. Five-year liver transplantation-free survival was 69%. A FIB-4 score ≥ 3·25 and ≥1 risk factor for cirrhosis were associated with poor liver transplantation-free survival. Liver disease was more frequent in patients with TRG mutations than in the paired control group [80/396, (20%)], OR 12.9 (CI 95%: 7.8-21.3, p < 0.001). CONCLUSIONS: TRG mutations significantly increase the risk of developing liver disease. Although symptoms may be mild, they may be associated with severe disease. Porto-sinusoidal vascular disease and cirrhosis were the most frequent lesions, suggesting that the mechanism of action is multifactorial.
引用
- Sidali S, Borie R, Sicre de Fontbrune F, et al. Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors. Hepatology. 2023. PMID: 37934624. doi:10.1097/HEP.0000000000000667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。